Venofer denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for venofer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Venofer as Not FDA-Approved

This denial reason for Venofer (iron sucrose injection) almost always reflects a coding or indication mismatch rather than a fundamental coverage exclusion. Venofer holds FDA approval for specific indications, and Cigna will cover it for those approved uses. A "not FDA-approved" denial typically means the diagnosis code submitted on the claim did not align with Venofer's approved indications as Cigna's system interprets them, or that the claim was for an off-label use that Cigna does not separately recognize in its coverage policies.

## Why This Denial Is Appealable

If the patient's clinical situation falls within Venofer's FDA-approved labeling, the appeal is straightforward: document the approved indication, confirm the diagnosis, and demonstrate the claim matches. If the use is off-label, the appeal requires demonstrating that the use is supported by established clinical evidence and recognized in the applicable specialty society guidelines — Cigna's own policies typically allow coverage of off-label uses meeting these standards. In either case, the denial is factually disputable with proper documentation.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial notice. Cigna must respond within 30 days (pre-service) or 60 days (post-service).
• Expedited review: Available within 72 hours for clinically urgent situations.
• External review (ACA §2719 / ERISA §503): After a final internal adverse decision, request IRO external review within approximately 4 months. The IRO's decision binds Cigna.

## Documentation to Gather

• FDA-approved prescribing information: A copy of the current Venofer label with the approved indication(s) highlighted — confirm the patient's diagnosis maps to an approved use.
• Diagnosis documentation: Chart notes and lab results confirming the patient's specific condition and how it aligns with the FDA-approved indication.
• Claim coding review: Confirm with the billing provider that the ICD-10 diagnosis code(s) submitted accurately reflect the approved indication; a coding correction may resolve the denial without a full appeal.
• Prescriber medical-necessity letter: If the use is off-label, a letter from the treating physician explaining the clinical basis and citing applicable specialty society guideline support.
• Guideline reference: For any off-label use, reference the relevant specialty organization guideline that endorses the use in this clinical context.

## Criteria-Mapping Structure

Review Cigna's clinical policy bulletin for IV iron or Venofer. Identify each criterion distinguishing covered from non-covered indications. For each, cite the FDA label language or guideline reference, then the specific patient chart data confirming the use falls within covered parameters.